Epiford 500 CR Tablet contains a combination of Sodium Valproate (333 mg) and Valproic Acid (145 mg), formulated as a controlled-release preparation for the management of epilepsy and related neurological disorders. This medication acts primarily by increasing the availability of gamma-aminobutyric acid (GABA) in the brain, an inhibitory neurotransmitter that helps stabilize neuronal activity and prevent seizure propagation. Epiford 500 CR is indicated for the treatment of various seizure types including generalized tonic-clonic seizures, absence seizures, and complex partial seizures. The controlled-release formulation ensures a sustained therapeutic plasma concentration, improving compliance and minimizing peak-related side effects. Additionally, it may be used in the management of bipolar disorder and for migraine prophylaxis under specialist supervision. Dosage should be individualized based on clinical response and serum drug levels, with careful monitoring for adverse effects such as hepatotoxicity, thrombocytopenia, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment, mitochondrial disorders, or a history of pancreatitis. Regular liver function tests and blood counts are recommended during therapy. Epiford 500 CR should be prescribed and monitored by healthcare professionals experienced in epilepsy management to optimize therapeutic outcomes and minimize risks.